XOMA Corporation (XOMA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

XOMA Corporation (XOMA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

28.13

1.42 (5.32%)

At close: Jan 15, 2025, 3:59 PM

28.12

-0.04%

After-hours Jan 15, 2025, 04:00 PM EST

undefined% (undefined)

Bid	26.26
Market Cap	331.45M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.07
PE Ratio (ttm)	-9.16
Forward PE	n/a
Analyst	Buy

Ask	30.04
Volume	82,889
Avg. Volume (20D)	30,983
Open	27.07
Previous Close	26.71
Day's Range	27.07 - 28.96
52-Week Range	18.57 - 35.00
Beta	undefined

About XOMA

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 6, 1986

Employees 13

Stock Exchange NASDAQ

Ticker Symbol XOMA

Website https://www.xoma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is $74, which is an increase of 163.06% from the latest price.

Buy 66.67%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

XOMA Corporation is scheduled to release its earnings on Mar 7, 2025, before market opens.
Analysts project revenue of $6.89M, reflecting a 282.78% YoY growth and earnings per share of -0.39, making a -79.14% decrease YoY.

Why Price Moved

1 month ago · Source

-3.05%

XOMA Royalty shares are trading higher after the c... Unlock content with Pro Subscription

News

2 months ago · zacks.com

What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.

3 months ago · seekingalpha.com

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's pref...